Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
EMBO J. 2004 Jul 21;23(14):2707-12. Epub 2004 Jul 1.

Defective downregulation of receptor tyrosine kinases in cancer.

Author information

  • 1Department of Biochemistry, Norwegian Radium Hospital, Montebello, Oslo, Norway.

Abstract

Most growth factors control cellular functions by activating specific receptor tyrosine kinases (RTKs). While overactivation of RTK signalling pathways is strongly associated with carcinogenesis, it is becoming increasingly clear that impaired deactivation of RTKs may also be a mechanism in cancer. A major deactivation pathway, receptor downregulation, involves ligand-induced endocytosis of the RTK and subsequent degradation in lysosomes. A complex molecular machinery that uses the small protein ubiquitin as a key regulator assures proper endocytosis and degradation of RTKs. Here we discuss evidence that implicates deregulation of this machinery in cancer.

PMID:
15229652
[PubMed - indexed for MEDLINE]
PMCID:
PMC514952
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk